معرفی
Mary Michele Barden, MD is an Assistant Professor of Neurology (Neuro-Oncology) at Yale School of Medicine and serves as Director of the Neuro-Oncology Fellowship Program. She provides comprehensive care for patients with brain tumors as part of the Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center.
Her clinical expertise focuses on neuro-oncology with special attention to the neurological challenges that arise from brain tumors. Dr. Barden emphasizes a holistic approach to patient care that addresses not just the tumor itself but also the functional impacts on language, memory, mobility, and independence. She advocates for multidisciplinary care involving social workers, oncology care coordinators, and palliative care providers.
Dr. Barden's research interests center on brain tumor treatment advances, particularly in glioblastoma. Her publication Top advances of the year: Neuro-oncology highlights key developments in the field, reflecting her focus on clinical trial participation and innovative treatment approaches for patients with brain cancers.
Scientific Awards:
- Attending of the Year (June 12, 2024)
Dr. Barden is actively involved in clinical trials research, serving as Sub Investigator for multiple studies including a Phase 0/I Trial of Anti-TIGIT Antibody AB154 for Recurrent Glioblastoma and the GBM AGILE international platform trial. She strongly encourages patients to discuss clinical trial options with their doctors to understand all available treatment approaches.
She works within the Brain Tumor Center at Smilow Cancer Hospital, collaborating with a multidisciplinary team of neuropathologists, radiation oncologists, neuroradiologists, and neurosurgeons to provide comprehensive care for patients with brain tumors.